Name | Number of supported studies | Average coverage | |
---|---|---|---|
epithelial cell | 3 studies | 19% ± 3% |
Insufficient scRNA-seq data for expression of WDR83 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
pancreas | 100% | 201.30 | 328 / 328 | 100% | 4.20 | 178 / 178 |
thymus | 100% | 368.63 | 653 / 653 | 100% | 5.62 | 605 / 605 |
uterus | 100% | 335.99 | 170 / 170 | 100% | 5.55 | 459 / 459 |
brain | 100% | 441.52 | 2641 / 2642 | 100% | 6.75 | 705 / 705 |
prostate | 100% | 399.45 | 245 / 245 | 100% | 5.54 | 501 / 502 |
adrenal gland | 100% | 328.95 | 258 / 258 | 100% | 5.68 | 229 / 230 |
esophagus | 100% | 282.68 | 1445 / 1445 | 99% | 3.05 | 182 / 183 |
kidney | 100% | 321.36 | 89 / 89 | 99% | 4.16 | 895 / 901 |
ovary | 100% | 350.02 | 180 / 180 | 99% | 3.94 | 426 / 430 |
skin | 100% | 334.62 | 1809 / 1809 | 99% | 4.03 | 467 / 472 |
bladder | 100% | 319.76 | 21 / 21 | 99% | 4.84 | 498 / 504 |
intestine | 100% | 299.07 | 966 / 966 | 99% | 3.99 | 520 / 527 |
stomach | 100% | 266.80 | 359 / 359 | 98% | 3.37 | 281 / 286 |
lung | 100% | 250.87 | 576 / 578 | 98% | 3.27 | 1135 / 1155 |
liver | 100% | 156.20 | 226 / 226 | 98% | 3.39 | 397 / 406 |
breast | 100% | 284.98 | 459 / 459 | 97% | 4.17 | 1089 / 1118 |
eye | 0% | 0 | 0 / 0 | 100% | 5.25 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 9.82 | 29 / 29 |
spleen | 100% | 331.67 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 4.60 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 4.58 | 1 / 1 |
adipose | 100% | 250.86 | 1203 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 242.05 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 99% | 189.85 | 851 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 94% | 184.52 | 871 / 929 | 0% | 0 | 0 / 0 |
muscle | 93% | 107.31 | 748 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0000398 | Biological process | mRNA splicing, via spliceosome |
GO_0090594 | Biological process | inflammatory response to wounding |
GO_0043122 | Biological process | regulation of canonical NF-kappaB signal transduction |
GO_0000375 | Biological process | RNA splicing, via transesterification reactions |
GO_0001666 | Biological process | response to hypoxia |
GO_0032496 | Biological process | response to lipopolysaccharide |
GO_0010008 | Cellular component | endosome membrane |
GO_0005764 | Cellular component | lysosome |
GO_0071013 | Cellular component | catalytic step 2 spliceosome |
GO_0005681 | Cellular component | spliceosomal complex |
GO_0005515 | Molecular function | protein binding |
Gene name | WDR83 |
Protein name | WD repeat domain-containing protein 83 (Mitogen-activated protein kinase organizer 1) (MAPK organizer 1) WD repeat domain-containing protein 83 (Mitogen-activated protein kinase organizer 1) |
Synonyms | MORG1 hCG_172499 |
Description | FUNCTION: Molecular scaffold protein for various multimeric protein complexes. Acts as a module in the assembly of a multicomponent scaffold for the ERK pathway, linking ERK responses to specific agonists. At low concentrations it enhances ERK activation, whereas high concentrations lead to the inhibition of ERK activation. Also involved in response to hypoxia by acting as a negative regulator of HIF1A/HIF-1-alpha via its interaction with EGLN3/PHD3. May promote degradation of HIF1A. May act by recruiting signaling complexes to a specific upstream activator (By similarity). May also be involved in pre-mRNA splicing. . |
Accessions | ENST00000418543.8 Q9BRX9 F8VSE4 ENST00000547481.5 H7C0S9 G3V221 ENST00000553179.5 ENST00000548381.5 H0YIE8 ENST00000547797.1 ENST00000425834.7 |